Eliem Therapeutics logo
Eliem Therapeutics
ELYM | NASDAQ
Chart Builder DCF Calculator
$5.11
-$0.05 (-0.97%)
At close: Oct 02, 2024, 04:00 PM ET

Eliem Therapeutics Company Profile

Company profile explained

Company Profile

Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic solutions for conditions characterized by abnormal neuronal excitability. The company aims to fulfill significant unmet medical needs in areas such as chronic pain management, neuropsychiatric illnesses, epilepsy, and other disorders affecting the central and peripheral nervous systems. Their developmental pipeline is highlighted by two primary drug candidates. ETX-810 is currently in Phase IIa clinical studies for the treatment of chronic pain. The second key candidate, ETX-155, is undergoing Phase I clinical trials, with potential applications for major depressive disorder, perimenopausal depression, and focal onset seizures. Beyond these lead assets, Eliem is also cultivating several preclinical programs, including a Kv7 Program targeting pain, epilepsy, and depression, and an Anxiolytic program specifically designed for generalized anxiety disorder. Eliem Therapeutics, Inc. was established in 2018 and is headquartered in Redmond, Washington.

Key Executives

Name Position
Aoife Brennan BCh MMSc Chief Executive Officer, President & Director
Brett Kaplan Chief Operating Officer & Principal Financial Officer
Andrew Levin Principal Financial Officer, Co-Founder & Executive Chairman
Emily Pimblett Chief Accounting Officer
Jo Palmer-Phillips Chief Development Officer
Nishi Rampal Senior Vice President of Clinical Development
Valerie Morisset Chief Scientific Officer and Executive Vice President of Research & Development

Latest SEC Filings

Date Type Title
Sep 30, 2026 4 Filing
Sep 17, 2026 4 Filing
Sep 03, 2026 8-K Current Report
Aug 14, 2026 8-K Current Report
Aug 06, 2026 10-Q Quarterly Report
Aug 06, 2026 8-K Current Report
Jul 08, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 07, 2026 SC 13D/A [Amend] Filing
Jul 01, 2026 4 Filing
Jul 01, 2026 4 Filing
View All SEC Filings ➞
Eliem Therapeutics
Eliem Therapeutics logo
Country United States
IPO Date Aug 10, 2021
Industry Biotechnology
Sector Healthcare
Employees 9
CEO Aoife M. Brennan BAO, BCh, MB, MMSc

Contact Details

23515 NE Novelty Hill Road Redmond, Washington 98053 United States

Stock Details

Ticker Symbol ELYM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001768446
CUSIP Number 28658R106
ISIN Number US28658R1068
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.